Get the Stockscreener App
0.5121
2.18%
0.012
Leap Therapeutics Inc stock is traded at $0.5121, with a volume of 732.94K.
It is up +2.18% in the last 24 hours and down -85.32% over the past month.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
See More
Previous Close:
$0.5001
Open:
$0.4975
24h Volume:
732.94K
Relative Volume:
1.05
Market Cap:
$19.16M
Revenue:
$1.50M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.3066
EPS:
-1.67
Net Cash Flow:
$-55.17M
1W Performance:
-8.77%
1M Performance:
-85.32%
6M Performance:
-74.58%
1Y Performance:
-85.40%
1-Day Range:
$0.49
$0.5252
1-Week Range:
$0.48
$0.5568
52-Week Range:
$0.48
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.5121 | 19.16M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.19 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.89 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-29-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Get in on Leap Therapeutics Inc’s (LPTX) buy-in window today! - SETE News
Leap Therapeutics Inc (LPTX) stock analysis: A simple moving average approach - US Post News
What is HC Wainwright's Estimate for LPTX FY2029 Earnings? - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Downgraded by Baird R W to "Hold" - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Cut to "Neutral" at Robert W. Baird - MarketBeat
FY2029 Earnings Estimate for LPTX Issued By HC Wainwright - Defense World
Robert W. Baird Downgrades Leap Therapeutics (NASDAQ:LPTX) to Neutral - Defense World
Leap Therapeutics (NASDAQ:LPTX) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Leap Therapeutics Reports Promising Initial Clinical Data, Updates Corporate Presentation - Defense World
Baird R W Downgrades Leap Therapeutics (NASDAQ:LPTX) to Hold - Defense World
Leap reports positive colorectal cancer study results - MSN
Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral - MSN
Baird cuts Leap Therapeutics stock rating, slashes target - MSN
Leap Therapeutics stock hits 52-week low at $0.8 - MSN
Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback - MSN
Leap Therapeutics Shares Tumble After Downgrades from Baird, HC Wainwright -January 29, 2025 at 03:02 pm EST - Marketscreener.com
Leap Therapeutics stock cut to Neutral at Baird (LPTX:NASDAQ) - Seeking Alpha
This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Baird Downgrades Leap Therapeutics to Neutral From Outperform, Cuts Price Target to $1.25 From $9 - Marketscreener.com
HC Wainwright Downgrades Leap Therapeutics to Neutral From Buy -January 29, 2025 at 07:17 am EST - Marketscreener.com
Leap halts gastric cancer program, changes course - The Pharma Letter
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline - MSN
Leap Therapeutics stock hits 52-week low at $0.8 By Investing.com - Investing.com Nigeria
Health Care Cos Down Amid Rotation into Tech -- Health Care Roundup -January 28, 2025 at 05:45 pm EST - Marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Leap Therapeutics Shares Drop After Discontinuing Phase 3 Studies of Gastric Cancer Treatment - Marketscreener.com
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipe - Asianet Newsable
Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer - MSN
Why Is Leap Therapeutics Stock Trading Lower On Tuesday?Leap Therapeutics (NASDAQ:LPTX) - Benzinga
Gold Gains 1%; Boeing Shares Rise Following Q4 Results - Benzinga
Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining (NASDAQ:LPTX) - Seeking Alpha
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results - Benzinga
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings - Benzinga
Leap reports positive colorectal cancer study results By Investing.com - Investing.com South Africa
Leap crashes as midphase data mark end of gastric cancer program - Fierce Biotech
Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results - MarketWatch
Leap stock tumbles on mid-stage trial setback (LPTX:NASDAQ) - Seeking Alpha
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study - Yahoo Finance
Delayed Dream Sleep Linked to Alzheimer's Risk - 69News WFMZ-TV
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):